The HER2 oncogene is overexpressed or amplified in 20% of breast cancers. HER2-positive cancer historically portends a poor prognosis, but the HER2-targeted therapy trastuzumab mitigates this otherwise ominous distinction. Nevertheless, some patients suffer disease recurrence despite trastuzumab, and metastatic disease remains largely incurable due to innate and acquired resistance. Thus, understanding trastuzumab resistance remains an unmet medical need. Through RNAi screening, we discovered that knockdown of the serine/threonine phosphatase PPM1H confers trastuzumab resistance via reduction in protein levels of the tumour suppressor p27. PPM1H dephosphorylates p27 at threonine 187, thus removing a signal for proteasomal degradation. We further determined that patients whose tumours express low levels of 
Introduction
Trastuzumab (Herceptin ® ) is an anti-human epidermal growth factor receptor 2 (HER2, ERBB2) therapeutic monoclonal antibody that provides significant clinical benefit for breast cancer patients whose tumors exhibit overexpression or amplification of the oncogene HER2 (1). Trastuzumab acts, at least in part, by blocking the interaction between overexpressed HER2 and its dimerization partner HER3, resulting in inhibition of oncogenic PI3K pathway signaling and subsequent upregulation of the cyclin dependent kinase (CDK) inhibitor p27 (2-7). PI3K pathway inhibition also causes translocation of p27 from the cytoplasm to the nucleus, where it is able to inhibit CDK/cyclin complexes (8) (9) (10) .
Due to the molecular heterogeneity of cancer, not all patients with HER2-amplified tumors respond to HER2-targeted agents. In the metastatic setting, those that derive initial benefit often exhibit evolution of the tumor with resultant progression on therapy. One major hypothesis on the mechanism of resistance to HER2-targeted therapy is that the PI3K pathway may be independently activated downstream of the HER2-HER3 receptor complex via loss of PTEN or acquisition of activating PIK3CA mutations (2, 11, 12) . A recent preclinical study demonstrates that trastuzumabresistant models harboring PTEN loss or PIK3CA activating mutations are sensitive to GDC-0941, a class 1A PI3K small molecule inhibitor (2) . This finding illustrates how understanding the molecular nature of resistance can reveal potentially more effective diagnostic/therapeutic co-development strategies to better treat individual patients.
While PTEN loss and PIK3CA activating mutations may play a role in trastuzumab resistance, we hypothesized that there could be additional resistance factors for several reasons. First, the PI3K signalling pathway is known to elicit a complex network of downstream events which may involve regulatory factors other than PTEN and PIK3CA (13) . Second, there is ample evidence that the HER2/3 complex may
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Results

siRNA screen for trastuzumab resistance genes
To determine if there are additional downstream trastuzumab resistance factors other than PTEN and PIK3CA, we conducted a functional screen to identify genes that, upon silencing, augment proliferation of trastuzumab-treated BT474 (HER2-amplified) breast cancer cells (Fig. 1A) . Small interfering RNA (siRNA) knockdown of either p27 or PTEN increased proliferation in the presence of trastuzumab, consistent with the literature (11, 12, (15) (16) (17) (Fig. 1B) . Notably, knockdown of p27 was more potent at abrogating trastuzumab response than was knockdown of PTEN. Both PTEN and p27 siRNAs were used as positive controls as we screened siRNA libraries of human kinases (795 genes) and phosphatases (159 genes). Each gene was targeted separately by four individual siRNA oligonucleotides, and the relative cell growth was assessed via 3 H-thymidine incorporation. Knockdown of 31 genes yielded significantly increased proliferation (Z-score >1.5) with at least 2 of the 4 independent siRNA oligonucleotides and were validated in a repeat assay (Table 1) . Included in the libraries were siRNA oligonucleotides targeting PTEN and p27 (CDKN1B), and both of these positive controls were identified as hits (Fig. 1C) , further validating the method of screening.
The initial screen hits were further prioritized by testing reproducibility in other HER2-overexpressing cell lines (BT474M1, SKBR-3), by assessing potency of phenotype, and by testing robustness of gene knockdown by qRT-PCR. Aside from PTEN and p27, 3 kinases (DYRK1A, STK10, and STYK1) and 2 phosphatases (PPM1H and PTPN11) were identified based on these criteria as being the top hits ( Fig.   2A , Supplementary Fig. S1 ). Gene knockdown increased cell proliferation not only in the presence of trastuzumab, but also in the absence of trastuzumab. Thus, the evidence suggests that while these genes may have a role in trastuzumab resistance, they are not
Research. 
PPM1H loss causes trastuzumab resistance
Of the 5 top hits, knockdown of PPM1H stood out as being the most potent at augmenting proliferation in the presence of trastuzumab ( Fig. 2A) , thus we focused on better understanding the role of PPM1H in cell proliferation and trastuzumab resistance.
PPM1H is a member of the PP2C family of ser/thr phosphatases distinguished by the dependence on Mn 2+ or Mg 2+ for catalytic activity (18) . Although PPM1H was recently implicated as an oncogene in colon cancer (19, 20) , it was originally identified as a negative regulator of neurite outgrowth (21) . In fact, many PP2C family members have been described as negative regulators of growth having substrates in the PI3K pathway, the JNK pathway, or in cell cycle regulation (e.g. cyclin dependent kinases) (18) . Very little is known about the mechanism of PPM1H and how it might impact proliferation.
The same phenotype was observed with 3 of 4 independent siRNA oligonucleotides targeting PPM1H, ( Supplementary Fig. S1 ), suggesting that the proliferative effect is not likely due to off-target activity. Nevertheless, to further rule out any possibility of off target effects, PPM1H shRNA was transfected into BT474 cells along with a control vector or a PPM1H expression vector carrying synonymous mutations within the shRNA targeted region, thus rendering the exogenous transcript resistant to knockdown. The PPM1H shRNA caused trastuzumab resistance, similar to the result with siRNA (Fig. 2B) . However, when PPM1H shRNA was co-expressed with PPM1H carrying synonymous mutations, trastuzumab sensitivity was restored (Fig. 2B) , providing further evidence that the observation with PPM1H is not likely due to off-target effects.
Research. Many studies have suggested that 3D culture may more closely mimic the milieu of a tumour mass (22) . To determine the impact of PPM1H knockdown in 3D culture, we created stable BT474M1 cell lines carrying doxycycline (dox)-inducible PPM1H
shRNA. Treatment of the cell line with dox in 2D culture resulted in PPM1H knockdown at the mRNA and protein level and resulted in trastuzumab resistance, much like PPM1H siRNA. The same cell line was grown in 3D culture for 10 days in the presence or absence of dox, after which colony size was visualized and quantified. In the absence of dox, trastuzumab treatment resulted in significantly smaller colony size compared to untreated colonies; in the presence of dox, the trastuzumab effect was significantly diminished (Fig. 2C and Supplementary Fig. S1 ). PPM1H knockdown was verified at the protein level in the 3D culture model, and dox treatment of a negative control inducible LacZ shRNA cell line did not impact the trastuzumab effect ( Supplementary Fig. S1 ). Thus, the phenotype observed in 3D culture supports the conclusion that PPM1H knockdown augments cell growth and causes trastuzumab resistance.
PPM1H is a p27 T187 phosphatase
To elucidate the molecular mechanism of PPM1H in cell proliferation, we examined the effect of PPM1H knockdown on the PI3K-Akt pathway, a key oncogenic signalling axis in HER2-amplified cells (23, 24) . We speculated that the phosphatase activity of PPM1H might inactivate this pathway since PHLPP, a PPM1H-related family member, has previously been shown to dephosphorylate AKT (25) . However, knockdown of PPM1H did not change the phosphorylation levels of AKT, HER2 or HER3. Furthermore, there was no evidence for modulation of the MAPK pathway as assessed by pERK ( Supplementary Fig. S2 ).
We next examined the CDK inhibitor p27 and found significant modulation with PPM1H knockdown compared to both untreated and trastuzumab-treated control cells. p27 protein levels as assessed by Western blot and immunofluorescence dropped with PPM1H knockdown (Fig. 3A, B) , and this was supported by quantitative image analysis of the immunofluorescence (Supplementary Fig. S2 ), consistent with the observed increase in cell proliferation. No change in p27 mRNA levels was observed with PPM1H knockdown, suggesting that loss of p27 is due to an alteration in protein stabilization.
p27 is known to undergo ubiquitin-mediated proteasomal degradation which is initiated by phosphorylation of p27 at T187 by CDK2 in complex with cyclin A or E (26, 27) . T187 phospho-p27 is recognized by the F-box protein SKP2 which brings p27 to the COP9 signalosome (CSN) for ubiquitylation (28) . Recently SKP2 was shown to be phosphorylated and stabilized by AKT1 at S72 (29, 30) . However, p27 also plays a role in regulating SKP2 via inhibition of CDK2 resulting in dephosphorylation and destabilization of SKP2 (31) . Given this reciprocal regulation of p27 and SKP2, we hypothesized that PPM1H knockdown might be associated with increased SKP2
protein. This hypothesis was tested via Western blot and immunofluorescence, and the results clearly indicate that SKP2 protein increases while p27 decreases in the setting of PPM1H knockdown (Fig. 3 A, C and Supplementary Fig. S2 ). No change in SKP2 mRNA was observed, consistent with the conclusion that PPM1H knockdown promotes SKP2 protein stability.
Because PPM1H belongs to a ser/thr phosphatase family, it is possible that PPM1H might directly dephosphorylate p27 or SKP2. To explore these hypotheses, we first examined the subcellular localization of PPM1H. Nuclear/cytoplasmic fractionation revealed that PPM1H is present in both the nucleus and the cytoplasm ( Supplementary Fig. S3A ). Enzymatically active recombinant flag-PPM1H was then screened for activity on in vitro synthesized phospho-peptides representing the major known phosphorylation sites on p27 (S10, T157, T187) and SKP2 (S72, S75, S64). Liberation of phosphate was observed with the p27 peptides, most notably with the T187 peptide (Fig. 4A) . No evidence for PPM1H mediated dephosphorylation of the SKP2 phospho-peptides was observed.
To further examine a potential role for PPM1H in dephosphorylating p27, HAtagged p27 bound to anti-HA conjugated agarose beads was incubated in vitro with CDK2/cyclin A to phosphorylate T187. After washing 3 times to remove the CDK2/cyclin A, the phosphorylated p27 was subsequently incubated with flag-PPM1H or flag-PPM1H-H153L in ATP-free buffer. The H153L mutant was predicted to disrupt enzyme activity based on a prior mutational analysis of murine PPM1B (32) . Indeed the PPM1H-H153L mutant was found to have decreased enzymatic activity in a synthetic phosphatase assay ( Supplementary Fig. S3B ). Wildtype PPM1H but not PPM1H-H153L dephosphorylated p27 at T187 (Fig. 4B ). The pre-phosphatase (lower gel) and post-phosphatase (upper gel) phospho-T187 bands were quantified by densitometry which suggested that PPM1H diminished phosphorylation by about half.
Although there appears to be more phospho-T187 in the PPM1H-H153L treated lane (upper gel), the pre-phosphatase control reveals that this sample had more phospho-T187 before the addition of phosphatase, and the quantified ratio is 1.1, indicating little to no change with PPM1H-H153L treatment. While the S10 site on p27 was not phosphorylated by CDK2/cyclin A, there was some endogenous phosphorylation observed. PPM1H exhibited no activity at the S10 site in this assay, suggesting specificity for T187.
Specificity of PPM1H was further explored via GST-tagged versions of PPM1H
and the most closely related family member PPM1J. GST-PPM1H and GST-PPM1J exhibited similar enzymatic activity in a synthetic phosphatase assay ( Supplementary   Fig. S3C ) but only PPM1H was effective at dephosphorylating p27 at T187 (Fig. 4C ).
Research. Neither enzyme exhibited activity at S10. Together these data further support the hypothesis that PPM1H is a specific p27-T187 phosphatase.
Although PPM1H did not exhibit activity on SKP2 phosphopeptides, we nevertheless tested flag-PPM1H on full length SKP2. SKP2 was phosphorylated in vitro by AKT in the presence of γ-32 P-ATP and was then incubated with phosphatase.
λ-phosphatase was able to dephosphorylate SKP2 but PPM1H lacked activity ( Supplementary Fig. S3D ). These data further support the conclusion that unlike p27, SKP2 is not a substrate for PPM1H.
Tumors with low PPM1H expression trend toward worse clinical outcome
To explore whether expression of PPM1H might impact clinical outcome on trastuzumab, we developed an isotopic in situ hybridization probe to assay PPM1H Fig. S4 ). These data suggest that low PPM1H expression could be a poor prognostic indicator in HER2-positive patients treated with trastuzumab. Further work in larger clinical datasets would be warranted to explore the significance of this trend.
To determine if the observation with PPM1H was independent from known PI3K pathway prognostic markers, we examined PTEN expression and PIK3CA mutation status in the same trastuzumab-treated samples. Low PPM1H expression was independent of PIK3CA mutation and PTEN expression status. Interestingly, in this sample set, neither decreased PTEN expression nor PIK3CA hotspot mutations were associated with poor outcome either alone or in combination ( Supplementary Fig. S4 ).
In all cases in this sample set, PPM1H expression was observed to be low in normal breast epithelium and stroma, but appeared to be elevated in the epithelium of a proportion of the invasive breast cancers. In one case, PPM1H was observed to be elevated in pre-malignant glands (ductal carcinoma in situ), but was low in adjacent invasive cancer (Supplementary Fig. S4E ). This observation raises the possibility that PPM1H is upregulated earlier in the oncogenic process and in some cases is later downregulated. To further explore this possibility, we examined PPM1H expression in a database of 159 frozen breast tissue samples that had undergone gene expression profiling at Gene Logic (now Osimum Biosolutions). No clinical outcome data was available for this sample set. Although ductal carcinoma in situ was not included in this sample set, there was evidence for elevated PPM1H expression in some primary tumours compared to normal and benign fibrocyctic breast tissue. However, metastatic tumour tissue exhibited decreased PPM1H expression compared to primary tumours ( Supplementary Fig. S4F ). Taken together, the data are consistent with a pattern of 
PPM1H expression tending to be increased in early stages of disease and decreased at later stages.
PPM1H mRNA was also examined in a set of cell lines and cancer tissues representing the major breast cancer subtypes. The basal-like subtype tends to lack expression of ER, PR and HER2 and is associated with poor prognosis (34) . The luminal subtype expresses ER and PR, lacks HER2 amplification, and is associated with a better prognosis (34) . About 50% of HER2-positive cancers are ER-positive, and there are reports that ER status is reflected in expression profiles resulting in HER2-basal and HER2-luminal groups, with HER2-basal exhibiting a worse prognosis (17, 35) . Interestingly, breast cancer cell lines classified as basal or HER2-basal exhibited lower levels of PPM1H than did the luminal counterparts (Fig. 5B) . A similar observation was made in breast cancer tissues (Fig. 5C ). To determine whether HER2 pathway signalling might regulate PPM1H transcription, HER2 and HER3 were knocked down in BT474M1 cells, and PPM1H message was measured via qRT-PCR.
There was no evidence for PPM1H transcriptional regulation by HER2 or HER3 (Supplementary Fig. S4 ).
PPM1H mRNA was also examined in a broad database of normal and tumor gene expression (Gene Logic). We observed that PPM1H expression is significantly decreased in glioblastoma and in renal cell carcinoma compared to normal brain and kidney, respectively (Supplementary Fig. S4 ). Interestingly, PPM1H is significantly increased in colon adenocarcinoma and prostate adenocarcinoma compared to normal colon and prostate, respectively ( Supplementary Fig. S4 ). Thus, the role of PPM1H may depend upon the cancer type or even subtype.
Discussion
Diagnostic markers of poor outcome on therapy can be grouped into those that are prognostic (i.e. identify a particularly aggressive biology that is hard to treat) and those that are predictive of response to a specific therapy. Both types of diagnostic markers exhibit clinical utility and both can signify important disease biology. In the case of trastuzumab and lapatinib, prior bar code shRNA screens explored potential predictive markers of resistance by selecting for hits that impact long term cell growth in the setting of trastuzumab treatment, but not in the absence of treatment (11, 15) . With this approach, the tumour suppressor PTEN was identified as the only hit. In the present study, we took a broader approach, seeking to identify any gene that increased proliferation in the setting of trastuzumab treatment, even if it also did so without treatment. We also utilized a different platform, choosing to use siRNA and directly measure proliferation rather than relying on long-term cell growth assays. With this different approach, we identified several novel hits which we speculate may represent genes of broader prognostic significance.
The top novel trastuzumab resistance factor identified in the screen and after extensive validation was the PP2C family member PPM1H. The PP2C family consists of metal dependent ser/thr phosphatases of which there are 16 in humans (18) . The family is conserved throughout evolution with 7 PP2C family members existing in yeast (PTC1-7) (36). One important difference from other ser/thr phosphatase family members is that the PP2C family acts as monomers as opposed to requiring several subunits to achieve specifically targeted enzyme activity. The better characterized family members in humans include PPM1A and PPM1B which are negative regulators of growth and have been shown to dephosphorylate CDK2 as well as inhibit signalling through cellular stress pathways (18) . The yeast PP2C family members (PTC2 and 3) are also described as negative regulators of growth by dephosphorylating and inactivating Cdc28, a primary regulator of cell cycle progression (18) . Other family members such as PTC1 are negative regulators of osmotic stress signalling pathways (36) . Very little is known about PPM1H, although it was originally identified as a negative regulator of neurite outgrowth (21).
We explored whether PPM1H knockdown might impact total levels or phosphorylation of HER family members, immediate downstream PI3K or MAPK signalling components, or farther downstream cell cycle regulatory components. The only alteration that was consistently observed was a loss of nuclear p27, a key cell cycle regulator. This observation raised the hypothesis that PPM1H could be a phosphatase for p27, which we confirmed in vitro. Based on the existing data, we propose a model in which PPM1H dephosphorylates the T187 site on p27, thus preventing ubiquitylation and degradation (Fig. 6) . Stabilized p27 would then be available to inhibit the cell cycle. Knockdown of PPM1H causes loss of nuclear p27 without evidence of cytoplasmic re-localization, consistent with the model that there is increased phosphorylation of p27 at T187 and subsequent proteasomal degradation of p27 in the nucleus. If PPM1H acted on the S10 and/or T157 phosphorylation sites on p27, one would have predicted to see evidence of cytoplasmic translocation and retention of p27.
This work is the first that we are aware of linking PPM1H to regulation of p27.
This link raises interesting questions about what role PPM1H might play in regulating
the cell cycle not only in HER2-positive breast cancer as described here, but also in other cancer types and in normal cell cycle regulation. It should be noted that while the observation that PPM1H can dephosphorylate p27 at T187 is intriguing, it is nevertheless possible that PPM1H might also act as a phosphatase for other proteins still to be determined. Furthermore, the antibody developed to detect PPM1H identifies two bands, both of which disappear with knockdown. This observation suggests that there are 2 different forms of PPM1H. How these two forms differ molecularly and whether there are differences in substrate specificity or enzymatic activity is not known.
Consistent with the hypothesis that low PPM1H is associated with elevated proliferation, we found that there was a trend towards worse outcome in trastuzumabtreated patients whose tumours were HER2-amplified and had low PPM1H expression at the mRNA level. Based on the mechanism of PPM1H, this trend is consistent with many studies in the literature that have established low p27 expression and high SKP2 expression as poor prognostic indicators in breast cancer (26, (37) (38) (39) (40) (41) (42) (43) (44) . Furthermore, the cell cycle inhibitory activity of p27 on cyclin E/CDK2 complexes can be abrogated by cyclin D/CDK4 which binds p27 and titrates it away from cyclinE/CKD2. Interestingly, inactivation of both cyclin D and CDK4 are capable of inhibiting HER2 mediated tumorigenesis in genetically engineered mouse models, highlighting the importance of this cell cycle pathway in HER2 mediated oncogenesis (45) (46) (47) . It has also recently been observed that amplification or overexpression of cyclin E is a mechanism of trastuzuamb resistance (48) . These published data on cyclin/CDK complexes support the concept that a gene, such as PPM1H, that is involved in regulation of p27 could play a role in HER2 signaling and trastuzuamb resistance.
PPM1H expression was observed to be lower on average in the basal-like subtype of breast cancer which is well documented to be associated with poor prognosis. The basal-like expression pattern has also been reported to be associated with decreased p27 and increased SKP2 protein levels (39, 42) . It should be noted that while on average basal-like cancers have lower PPM1H expression, there are basal-like cancers that have PPM1H expression similar to luminal tumors. In fact, the trend toward low PPM1H being associated with poor outcome was observed in the ER-negative (i.e. basal-like) population in the sample set of HER2-positive tumors. We also observed that on average PPM1H expression was lower in metastatic compared to primary tumors, Isotopic in situ hybridization (ISH) was performed using a 591 bp probe starting at nucleotide 1597 of Genbank sequence NM_020700. The isotopically labelled slides were exposed to a phosphorimager which records the signal intensity per pixel.
Separately, H&E stained slides were marked for high tumor content areas. The signal intensity per marked unit area of tumor was then determined for each sample. The population was ranked from lowest to highest PPM1H signal intensity and the patients whose tumors were in the lower 50 th percentile for PPM1H expression were compared with those whose tumors were in the upper 50 th percentile for PPM1H via Kaplan-Meier analysis. The survival curves were compared via the log-rank (Mantel-Cox) test using GraphPad Prism software. A similar analysis was performed in ER-negative and ERpositive patients separately.
